» Articles » PMID: 29048368

The Structure of Human Neuromuscular Junctions: Some Unanswered Molecular Questions

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Oct 20
PMID 29048368
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

The commands that control animal movement are transmitted from motor neurons to their target muscle cells at the neuromuscular junctions (NMJs). The NMJs contain many protein species whose role in transmission depends not only on their inherent properties, but also on how they are distributed within the complex structure of the motor nerve terminal and the postsynaptic muscle membrane. These molecules mediate evoked chemical transmitter release from the nerve and the action of that transmitter on the muscle. Human NMJs are among the smallest known and release the smallest number of transmitter "quanta". By contrast, they have the most deeply infolded postsynaptic membranes, which help to amplify transmitter action. The same structural features that distinguish human NMJs make them particularly susceptible to pathological processes. While much has been learned about the molecules which mediate transmitter release and action, little is known about the molecular processes that control the growth of the cellular and subcellular components of the NMJ so as to give rise to its mature form. A major challenge for molecular biologists is to understand the molecular basis for the development and maintenance of functionally important aspects of NMJ structure, and thereby to point to new directions for treatment of diseases in which neuromuscular transmission is impaired.

Citing Articles

From in vivo models to in vitro bioengineered neuromuscular junctions for the study of Charcot-Marie-Tooth disease.

Scherrer C, Loret C, Vedrenne N, Buckley C, Lia A, Kermene V J Tissue Eng. 2025; 16:20417314241310508.

PMID: 40078221 PMC: 11898049. DOI: 10.1177/20417314241310508.


An α7 nicotinic and GABA receptor-mediated pathway controls acetylcholine release in the tripartite neuromuscular junction.

Petrov K, Lenina O, Leroy J, Bernard V, Germain T, Truong C J Physiol. 2024; 603(2):507-527.

PMID: 39740234 PMC: 11737540. DOI: 10.1113/JP287243.


Age-Related Homeostatic Plasticity at Rodent Neuromuscular Junctions.

Li Y, Badawi Y, Meriney S Cells. 2024; 13(20.

PMID: 39451202 PMC: 11506802. DOI: 10.3390/cells13201684.


Advances in Cholinesterase Inhibitor Research-An Overview of Preclinical Studies of Selected Organoruthenium(II) Complexes.

Zuzek M Int J Mol Sci. 2024; 25(16).

PMID: 39201735 PMC: 11354293. DOI: 10.3390/ijms25169049.


Functional and Structural Changes in Diaphragm Neuromuscular Junctions in Early Aging.

Tsentsevitsky A, Sibgatullina G, Odoshivkina Y, Khuzakhmetova V, Tokmakova A, Ponomareva A Int J Mol Sci. 2024; 25(16).

PMID: 39201644 PMC: 11354816. DOI: 10.3390/ijms25168959.


References
1.
Patton B, Miner J, Chiu A, Sanes J . Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J Cell Biol. 1998; 139(6):1507-21. PMC: 2132624. DOI: 10.1083/jcb.139.6.1507. View

2.
Hughes T . The early history of myasthenia gravis. Neuromuscul Disord. 2005; 15(12):878-86. DOI: 10.1016/j.nmd.2005.08.007. View

3.
Sanes J, Marshall L, McMahan U . Reinnervation of muscle fiber basal lamina after removal of myofibers. Differentiation of regenerating axons at original synaptic sites. J Cell Biol. 1978; 78(1):176-98. PMC: 2110176. DOI: 10.1083/jcb.78.1.176. View

4.
Wood S, Slater C . Safety factor at the neuromuscular junction. Prog Neurobiol. 2001; 64(4):393-429. DOI: 10.1016/s0301-0082(00)00055-1. View

5.
Slater C, Fawcett P, Walls T, Lyons P, Bailey S, Beeson D . Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain. 2006; 129(Pt 8):2061-76. DOI: 10.1093/brain/awl200. View